627results about How to "Inhibit the inflammatory response" patented technology

Methods and compositions for treating or ameliorating lower back pain by administering an effective amount of one or more cell types, alone, and / or in combination with a matrix, and / or in combination with growth factors, in order to stimulate lumbar angiogenesis, decrease inflammation, and stimulating regeneration.

Leukotriene A4 hydrolase (LTA4H) inhibitors, compositions containing them, and methods of use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and / or conditions associated with inflammation.

An unbranched polylactosamine comprising at least 6 monosaccharides and having terminal alpha 2->3 sialylation and internal alpha 1->3 fucosylation at various N-acetylglucosamine residues except for solely at the penultimate N-acetylglucosamine residue.

The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to Crohn's disease and / or their response to a particular drug or drugs.

Heparinase enzymes can be used as a medical treatment to reduce localized inflammatory responses. Treatment of activated endothelium with heparinase inhibits leukocyte rolling, adhesion and extravasation. Most of the heparin and heparan sulfate on endothelial cell surfaces and in basement membranes is degraded by exposure to heparinase. In addition, immobilized chemokines, which are attached to heparin / heparan sulfate on activated endothelium are solubilized by heparinase digestion. Heparinase can be infused into the vascular system to inhibit accumulation of leukocytes in inflamed tissue and decrease damage resulting from localized inflammations. Targeting of heparinase to activated endothelium can be accomplished through localized administration and / or use of genetically engineered heparinase containing endothelium ligand-binding domains.

There is provided a biocompatible electrode structure which is capable of being connected to an electronic circuit, and in which a conductive nanomaterial is dispersed into a polymeric medium, in which a density of the conductive nanomaterial on an opposite side of a connection surface to the electronic circuit, in the polymeric medium is lower than that on the side of the connection surface to the electronic circuit.

The present invention provides the use of ATP for the manufacture of a medicine for exerting a pharmacological effect when administered to a mammal, preferably a human, selected from the group consisting of: 1°. modulating inflammation by inhibiting the inflammatory response to a strong external insult such as endotoxin (LPS) and / or phytohaemagglutinin; 2°. exerting said inhibitory effect on inflammatory response to an external stimulus even under conditions of oxidative stress, 3°. exerting a local immuno-modulating and anti-inflammatory effect in the intestine, thus preventing intestinal damage induced by a non-steroid anti-inflammatory drug (NSAIDs), 4°. exerting an immuno-modulating and anti-inflammatory effect in human intestinal cells in vitro, 5°. alleviating pulmonary symptoms, such as shortness of breath and dyspnoea, in patients suffering from an obstructive pulmonary disease, and 6°. exerting favorable clinical effects with respect to certain mental and neurological disorders and aberrant conditions. The medicine is preferably manufactured in lyophilized form.

This invention provides pharmaceutical compositions containing lipoxin compounds and therapeutic uses for the compounds in treating or preventing a disease or condition associated with columnar epithelial inflammation. The invention also discloses methods for screening for compounds useful in preventing columnar epithelial inflammation.

The invention discloses a liquid wound dressing which is characterized by comprising the following raw materials in parts by weight: 100-180 parts of a medical polymer film forming material, 0-20 parts of chitosan, 10-25 parts of polyethylene glycol 400 and 10-28 parts of glycerin, wherein the medical polymer film forming material is one in polyvinyl alcohol and polyvinyl butyral or a mixture of carbomer and one in the polyvinyl alcohol and the polyvinyl butyral. The liquid wound dressing can absorb the wound exudate, can effectively debride, maintains the surface of a wound to be wet, promotes the wound healing and is good in sterilizing effect.

The invention relates to a postoperation anti-infectious composite electrostatic-spinning nanometer fiber-film sheet for repairing hernia and a preparation method thereof. The hernia-repairing sheet comprises a polymer nanometer fiber-membrane base sheet prepared through an electrostatic spinning method, and a biodegradable high-molecular nanometer fiber functional membrane which is connected with the polymer nanometer fiber-membrane base sheet, is loaded with an anti-infectious medicine and is obtained through an electrostatic spinning method. The polymer nanometer fiber-membrane base sheet is soft and good in mechanical properties, does not cause damage of internal organs and enables an internal organ to be fixedly disposed at a postoperation recovery position. The electrostatic-spinning nanometer fiber functional membrane loaded with the anti-infectious medicine has appropriate degradation speed, and the anti-infectious medicine is gradually released along with degradation of the material, so that postoperation infection and inflammation caused by wound pollution are effectively prevented. The hernia-repairing sheet is capable of effectively reducing inflammation reaction caused by postoperation infection and reducing patient pain after being implanted into a human body for repairing hernia.

The present invention relates to medicine material technology, and is especially one kind of antiphlogistic medicine and growth factor slow releasing system and its preparation process and application. The prepared nanometer fiber medicine carrying film may be used in surgical operation to resist inflammation as skin tissue engineering rack. As post-operational adhesion resisting film, the present invention is biodegradable and biocompatible and has antiphlogistic effect. At the same time, medicine is combined with growth factor in controlled release speed and used in skin tissue engineering to prevent inflammation and to release growth factor promoting skin cell regeneration and healing simultaneously. The present invention has wide application foreground in post-operational adhesion prevention and skin tissue engineering.

This invention provides pharmaceutical compositions containing lipoxin compounds and therapeutic uses for the compounds in treating or preventing a disease or condition associated with columnar epithelial inflammation. The invention also discloses methods for screening for compounds useful in preventing columnar epithelial inflammation.

The invention discloses multi-effect ceramide face cream. The multi-effect ceramide face cream is prepared from a component A and a components B, wherein the component A is prepared from, by weight, 60%-80% of water, 5%-10% of mineral oil, 2%-6% of glycerin, 1%-6% of butanediol, 1%-3% of cetyl alcohol, 1%-3% of sorbitan stearate, 1%-3% of polydimethylsiloxane, 1%-2% of beewax, 0.2%-0.5% of PEG-40 stearate and 0.2%-0.5% of cetyl palmitate, and the component B is prepared from, by weight, 0.1%-0.3% of phenoxyethanol, 0.1%-0.3% of laureth-9, 0.1%-0.2% of xanthan gum, 0.05%-0.12% of propyl hydroxybenzoate, 0.05%-0.12% of methylparaben, 0.05%-0.12% of Carbomer, 0.05%-0.12% of potassium acrylates / C10-30 alkyl acrylate crosspolymer, 0.02%-0.12% of sodium hydroxide, 0.00005%-0.00015% of phenylethyl resorcinol, 0.005%-0.012% of ceramide 2 and the like. The multi-effect ceramide face cream has the effects of whitening, moisturizing, wrinkle removing, aging resisting and allergy resisting.

The present invention provides novel and inventive biodegradable and biocompatible materials and methods of use in biomedical area. Inventive materials can be formed by blending PLGA with ACP or any one of their family members. Inventive materials can be used in making biodegradable products including but not limit to drug eluting stents, vascular graft, bone substitutes such as bone fixation screws, surgical sutures and anti-adhesive membranes, and / or drug-slow release control vehicle etc.

The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.

The invention relates to an anti-allergic composition for relieving as well as an application thereof. The anti-allergic composition for relieving comprises the following components: a first anti-allergic composition, a second anti-allergic composition, an anti-allergic peptide composition, Crambe abyssinica seed oil, bisabolol, and a Cardiospermum halicacabum extract product; the active componentof the first anti-allergic composition comprises 4-tert-butylcyclohexanol and 2-(3-(4-hydroxyphenyl)propanamido)benzoic acid; the active components of the second anti-allergic composition comprise anextract product of Stephania tetrandra, potassium lactate, phenoxyethanol, and dipotassium glycyrrhizinate; the active components of the anti-allergic composition comprise palmitoyl tripeptide-8 andacetyl tetrapeptide-15. The anti-allergic composition for relieving is evaluated by a macrophage nitric oxide inflammation releasing model, inhibition rate of nitric oxide releasing reaches 46.07%, and inhibition rate of histamine reaches 61.59%.

The invention discloses a protecting and fixing device for wound, comprising at least one protecting and fixing layer with openings, wherein the protecting and fixing layer with openings is longitudinally provided with an opening for communicating the upper end face and the lower end face; the opening can enclose the wound therein so as to make the protecting and fixing layer with openings limit the wound tension and increase the mobile corrugation of the wounded skin. The invention can protect and fix the operation wound, the trauma wound or the catheter infusion wound into an opening which can limit the tension increase of the wound and the mobile corrugation of the surface skin of the wound and can prevent the wound from being torn and cracked and also avoid the damage for the wound due to the mobile corrugation and the surgical dressing of the wounded skin as well as the relative displacement frictions of the infusion catheter. Therefore, the invention fills the blank of current technology, which can enable the covered dressings to penetratively contact the secretion so as to absorb the exudate of the wound. Besides, the invention can prevent the foreign material contact anaphylaxis due to the wound contacting by compressing the dressing and the direct bonding of the catheter infusion wound and can prevent the re-injury of the wound caused by the synechia between the dressing and the wound secretion.

Nucleic acid sequences and corresponding translated products of novel mutant forms of the Drosophila hid gene are described. Such sequences and products are useful in screening methods for identifying and testing antagonists of Hid phosphorylation, in particular, compositions modifying MAPK phosphorylation of Hid.

The invention discloses a non-toxic environment-friendly solvent type double-layer nanofiber skin dressing and a preparation method thereof. The non-toxic environment-friendly solvent type double-layer nanofiber skin dressing comprises a drug-loaded hydrophilic repair natural polymer fiber layer and a waterproof and breathable synthetic polymer fiber layer, and is prepared by adopting a non-toxicenvironment-friendly solvent system through an electrostatic spinning technology layer by layer. The preparation method comprises the steps that a natural polymer and a drug are dissolved in a non-toxic environment-friendly solvent, and a cross-linking agent is added; a synthetic polymer is dissolved in the non-toxic environment-friendly solvent, and a water repellent agent is added; and a naturalpolymer solution and a synthetic polymer solution are placed in an injection syringe, and an electrostatic spinning device is adopted for spinning to prepare a double-layer fiber membrane. The double-layer nanofiber skin dressing prepared through the preparation method does not contain a toxic solvent, and does not generating toxic and side effects on open wounds when serving as the dressing; andthe double-layer nanofiber skin dressing has waterproof and breathable performance, is good in cytocompatibility, can promote wound healing of rats with skin damages, and has the huge application prospects in the field of skin dressings.

A medicine coated scaffold for preventing and treating the renarrowing of arteria coronaria after plastic operation features that the tatin kind of medicines which can suppress the growth of new tunia intime and the reproduction of smooth muscle cells is contained in the coated layer of scaffold and can be slowly released to prevent said renarrowing of arteria coronaria. Its advantages are high effect and low cost.

Botanical compounds to modulate kinase activity are disclosed. The compounds and methods disclosed also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively. The compositions contain at least one fraction isolated or derived from hops or Acacia.

The invention discloses a steam eye patch and a making method thereof. Low-temperature steam at 40-50 DEG C can be generated, heating time can last for 20-40min, and the low-temperature steam can heatperiocular skin, accelerate blood circulation and improve cell activity, so that the steam eye patch has effects of relieving eye fatigue, moisten eyes and removing black eyes and eye bags; diatomitein a heating piece has adsorption performance, thereby being capable of effectively cleaning the periocular skin to enable steam to better permeate skin. The heating piece also contains macromolecular setting fiber, thereby having good setting effect; when in use, the steam eye patch can be adjusted timely according to eye shape of different users to better fit eyes; a healthcare skin lotion coated on the surface of inner-layer nonwoven cloth has good healthcare and skincare effects on human bodies, so that compared with conventional steam eye patches, the steam eye patch is richer in function. The making method is simple in process, mild in condition and suitable for mass industrial production of the steam eye patch.

The present invention relates to a use of a biological surfactant as an anti-inflammatory agent and a tissue preservative solution. More particularly, the present invention is directed to an anti-inflammatory agent and a tissue preservative solution comprising a biological surfactant which blocks a reaction of a proinflammatory factor with a receptor by emulsifying the proinflammatory factor.

The invention relates to an anti-allergy relieving composition and application thereof. The anti-allergy relieving composition is prepared from the following components: a first anti-allergy composition, a second anti-allergy composition and an anti-allergy peptide composition, wherein active components of the first anti-allergy composition comprise 4-tert-butylcyclohexanol and hydroxyphenyl propionamide benzoic acid; active components of the second anti-allergy composition comprise radix stephaniae tetrandrae extract, potassium lactate, phenoxyethanol and dipotassium glycyrrhizinate; active components of the anti-allergy peptide composition comprise palmitoyl tripeptide-8 and acetyl tetrapeptide-15. After the anti-allergy relieving composition provided by the invention is evaluated through a macrophage nitric oxide inflammatory release model, the inhibition rate on the nitric oxide is 38.62 percent and the inhibition rate on histamine is 41.92 percent.

The invention relates to the field of Chinese medicine preparation, in particular to a method for preparing tripterine nano structure lipid carrier containing traditional Chinese medicine monomer and application of the tripterine nano structure lipid carrier in preparation of transdermal drugs used for treating psoriasis, rheumatoid arthritis, skin cancer and breast cancer. The tripterine nano structure lipid carrier is characterized by comprising the following components in parts by weight: 1 part of tripterine, 5-100 parts of mixed lipid, 0.5-10 parts of phospholipid, 0.1-15 parts of poloxamer-188 and 0.5-10 parts of vitamin E and tocopherol polyethylene glycol succinate, wherein the mixed lipid is composed of solid lipid monoglycerine and liquid lipid octylic acid / caprin according to the weight ratio of 1: 0.1-10: 1. Tripterine is prepared into the nano structure lipid carrier, the tripterine nano structure lipid carrier in a semi-solid or liquid preparation form is applied in a transdermal way, bioavailability of the tripterine can be improved, toxic response of tripterine can be reduced, and the nano structure lipid carrier provided by the invention has great clinical application value in the improvement of the treatment effect of tripterine.

This invention provides pharmaceutical compositions containing lipoxin compounds and therapeutic uses for the compounds in treating or preventing a disease or condition associated with columnar epithelial inflammation. The invention also discloses methods for screening for compounds useful in preventing columnar epithelial inflammation.

The present invention relates to a fusion protein composed of the extracellular domain of PD-L1 and a modified immunoglobulin Fc region. The extracellular domain of PD-L1 and a fragment thereof have excellent immunomodulatory activity, and can be used as an immunomodulatory agent if a modified immunoglobulin Fc region is coupled thereto. Accordingly, the PD-L1 fusion protein according to the present invention demonstrated its excellent effect in disease models of inflammatory bowel disease, colitis, psoriasis, asthma and arthritis, and thus can be very effectively used for the treatment of such diseases.

The present invention relates to a pure Chinese medicine preparation. Jianwei Kangning Jiaonang capsule for curing the diseases of chronic gastritis, atrophic gastritis, gastro-duodenal ulcer, bile-regurgitational gastritis, functional dyspepsia, peptic ulcer, chronic hepatitis and chronic cholecystitis with obvious therapeutic effect and high cure rate. Said medicine is made up by using 21 Chinese medicinal materials of white peony root, pinellia tuber, poria, unceria stem and thorn, alpinia fruit, fennel fruit and others.

The present invention is one kind of medicine delayed releasing blood vessel rack capable of preventing post-operation blood vessel stenosis and its preparation process. The rack consists of siphonic blood vessel rack made of Ni-Ti memory alloy or stainless steel, porous ceramic film base layer of calcium phosphate attached to the siphonic blood vessel rack, and medicine carrying degradable surface layer attached to the porous ceramic film base layer of composite biodegradable polymer and specific medicine. The preparation process includes the steps of: machining blood vessel rack with proper material; surface activation of the blood vessel rack and two-step bionic deposition; and soaking the blood vessel rack with surface porous ceramic film base layer inside the mixture solution with specific medicine, biodegradable polymer and solvent.

The invention discloses a strychnos alkaloid vesicle and a preparation method thereof, and a preparation containing the strychnos alkaloid vesicle and a preparation method thereof, and belongs to the field of medicinal preparations. The strychnos alkaloid vesicle is prepared from strychnos alkaloid, a nonionic surfactant and an additive. The strychnos alkaloid vesicle is preferably prepared into an external gel preparation. The strychnos transdermal administration external preparation has unique advantages on the medicament that: a novel vesicle administration system is applied; trandermal absorption of the medicament is increased; the clinical treatment effects are enhanced; and the toxic and side effects during oral administration and parenteral administration are avoided. The strychnos alkaloid vesicle can be applied to treatment of rheumatoid arthritis, ankylosing spondylitis, and the like.